Abstract #5097

Efficacy of GelrinC in the treatment of chondral and osteochondral lesions: MRI results based on semi-quantitative MOCART scoring and T2 mapping

Markus Schreiner^1,2, Kitty Ohel³, Livnat Ben-Zur³, Sebastian Röhrich², Martin Zalaudek², Pavol Szomolanyi², Vladimir Juras², Vladimir Mlynarik², Reinhard Windhager¹, and Siegfried Trattnig^2,4

¹Department of Orthopaedics, Medical University of Vienna, Vienna, Austria, ²High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Regentis Biomaterials Ltd, Or Akiva, Israel, ⁴CD Laboratory for Clinical Molecular MR Imaging, Vienna, Austria

The treatment of femoral cartilage lesions still remains a challenge. Established cartilage repair techniques include microfracture (MFX), acellular scaffolds and cell based therapies such as ACI and MACI, which differ in associated morbidity and outcome. Therefore, there have been strong research efforts to develop novel treatment alternatives. In this study, we demonstrate that GelrinC, a novel acellular biodegradable implant, allows a successful treatment of both chondral and osteochondral femoral lesions in a minimal invasive one-step procedure. For both lesion types a substantial improvement of MOCART scores as well as T2 values has been demonstrated over a 24-month period.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.